Clinical Trials
21 trialsNCT07615101 2026-06-01
Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
Norroy Bioscience Co., LTD
Phase 3 Not yet recruiting
NCT07075185 2026-04-24
inMMyCAR
Kelonia Therapeutics, Inc.
Phase 1 Recruiting
NCT07216443 2026-04-15
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Phase 2 Recruiting
NCT06403436 2026-04-13
TT-CSP-001
TOLREMO therapeutics AG
Phase 1 Active not recruiting
NCT06726161 2026-04-13
GPC3
RayzeBio, Inc.
Phase 1/2 Recruiting
NCT07479381 2026-04-09
CLEAR
Harbinger Health
Terminated
NCT07168993 2026-03-18
BA-004
bioAffinity Technologies Inc.
Phase NA Recruiting
NCT06221397 2026-03-16
LEGIT_MC_EVCDA
AI Labs Group S.L
Completed
NCT07046260 2026-03-11
PROCARES
Harbinger Health
Recruiting
NCT07454603 2026-03-06
PROSTest_STRAT
Wren Laboratories LLC
Not yet recruiting
NCT07335003 2026-01-12
Study of the Photoprotection and Prevention of Actinic Damage With Anthelios Fluide 100 KA+ UVMune 400 in Patients With Multiple Actinic Keratoses
Cosmetique Active International
Phase NA Recruiting
NCT06145750 2025-11-24
FIRSTLUNG
Delfi Diagnostics Inc.
Phase NA Completed
NCT07244705 2025-11-24
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
Anbogen Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07069556 2025-11-21
ColoSense Post-Approval Study
Geneoscopy, Inc.
Recruiting
NCT05988645 2025-09-29
Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II)
MiWEndo Solutions S.L.
Phase NA Recruiting
NCT07189806 2025-09-24
MAPLE-UK
Hvivo
Recruiting
NCT04186845 2025-09-22
Spotlight
Blue Earth Diagnostics
Phase 3 Completed
NCT04410133 2025-08-28
REVELATE
Blue Earth Diagnostics
Phase 3 Completed
NCT06607783 2025-08-28
PREDICT
Gold Standard Phantoms
Not yet recruiting
NCT05578872 2025-08-26
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
Anaveon AG
Phase 1/2 Completed
NCT04410367 2025-07-20
PURSUE
Blue Earth Diagnostics
Phase 2 Completed